Finance

Lists
Why is RXRX down 4.35%?
Dive Deeper
RXRX:NASDAQ
Recursion Pharmaceuticals Inc
$3.18
-4.35%
(-0.14) 1D
Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RXRX...
Open
$3.33
High
$3.34
Low
$3.16
Mkt. cap
1.98B
Avg. vol.
27.70M
Volume
16.72M
52-wk high
$5.24
52-wk low
$2.77
EPS
-$0.89
Beta
1.15
Shares outstanding
622.76M
No. of employees
600
Open
$3.33
High
$3.34
Low
$3.16
Mkt. cap
1.98B
Avg. vol.
27.70M
Volume
16.72M
52-wk high
$5.24
52-wk low
$2.77
EPS
-$0.89
Beta
1.15
Shares outstanding
622.76M
No. of employees
600
News stories
From web sources and news partners
About Recursion Pharmaceuticals Inc
CEONajat Khan
Employees600
Founded2013
HeadquartersSalt Lake City, Utah, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 4 analysts giving stock ratings to RXRX in the past 3 months
Buy
Buy
2
Hold
2
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for RXRX in the last 3 months.
Highest
Current $3.18
$8.00 (+151.18%)
Average
$6.63 (+108.16%)
Lowest
$5.90 (+85.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alec Stranahan
Bank of America Securities
Hold
Maintained
$6.00
+88.4%
11/04/2026
Gil Blum
Needham
Buy
Reiterated
$8.00
+151.2%
10/19/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
$5.90
+85.2%
10/16/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
-
-
09/15/2026
Brendan Smith
TD Cowen
Hold
Maintained
-
-
08/05/2026
Last report
Nov 3, 2026
Fiscal period
Q3 2026
-$0.22 / -$0.23
+3.86%beat
Revenue / Est. (USD)
18.55M / 14.81M
+25.25%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
35.54M
6.47M
7.67M
18.55M
Cost of goods sold
110.22M
100.39M
101.10M
109.17M
Cost of revenue
110.22M
100.39M
101.10M
109.17M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
42.17M
34.59M
41.53M
32.56M
Operating expense
42.17M
34.59M
41.53M
32.56M
Total operating expenses
152.39M
134.98M
142.64M
141.73M
Operating income
-116.85M
-128.50M
-134.97M
-123.18M
Other non operating income
-6.03M
784.00K
-1.04M
-385.00K
EBT including unusual items
-108.10M
-122.11M
-131.01M
-119.01M
EBT excluding unusual items
-116.62M
-122.11M
-131.01M
-119.01M
Income tax expense
20.00K
-4.60M
-1.00K
25.00K
Effective tax rate
-0.02%
3.77%
-
-0.02%
Other operating expenses
-
-
-
-
Net income
-108.12M
-117.50M
-131.00M
-119.04M
Net profit margin
-304.24%
-1,815.57%
-1,708.02%
-641.63%
Earnings per share
-0.21
-0.22
-0.25
-0.22
Interest and investment income
6.26M
5.96M
5.31M
4.82M
Interest expense
-
-350.00K
-309.00K
-266.00K
Net interest expenses
6.26M
5.61M
5.00M
4.55M
Depreciation and amortization charges
-
-
-
-
EBITDA
-97.37M
-108.83M
-116.80M
-106.64M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps